Kincell Bio and Cellipont Merge to Form Kincellis Advanced Therapies
- Kincell Bio and Cellipont Bioservices completed merger to create Kincellis Advanced Therapies, a U.S.-based CDMO specializing in cell and advanced therapies.
- Kincellis operates 140,000 sq ft across three U.S. sites (Florida, North Carolina, Texas) with 16 qualified GMP manufacturing suites supporting early development through commercial supply.
- Combined entity has released 150+ GMP batches, supports 10 IND filings in 2026, and employs 200+ staff; merger funded by NewSpring Capital, Kineticos, HealthQuest, and Great Point Partners.
Operational Impact
Kincellis' consolidated 16-suite GMP footprint across Florida, North Carolina, and Texas adds dedicated cell-therapy manufacturing capacity for autologous and allogeneic programs, with active support for 10 IND filings and 150+ released batches positioning the merged entity as a scaled competitor in advanced-modality CDMO services.
Source: PharmaSource RSS
Quotient Sciences' AI Algorithm Achieves Pharmacokinetic Target in Modified-Release Formulation Study
- AI algorithm selected formulation compositions and doses in a clinical trial, reaching preset pharmacokinetic targets within three dosing periods.
- Algorithm was trained on in vitro release data and retrained during the study using tablet dissolution and PK data from healthy volunteers.
- Quotient Sciences screened one-third fewer formulations than conventional methods during laboratory screening phase.
Operational Impact
Quotient Sciences' validated AI-guided formulation platform may accelerate drug-product development timelines and reduce formulation screening costs for CDMO clients pursuing modified-release generic and branded programs.
Source: PharmaSource RSS